Eagle Pharmaceuticals, which develops and sells enhanced injectable products, filed on Friday with the SEC to raise up to $50 million in an initial public offering. The Woodcliff Lake, NJ-based company, which was founded in 2007 and booked $14 million in sales for the fiscal year ended September 30, 2013, plans to list on the NASDAQ under the symbol EGRX. Eagle Pharmaceuticals initially filed confidentially on October 21, 2013. Piper Jaffray and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
